Science Advances

OCT 23, 2026 · JOURNAL ARTICLE

Primary tumor–derived lactate primes prostate cancer cells for a dormant fate

Science Advances

The metastatic outcome depends on the state of disseminated cancer cells (DCCs) leading to overt metastasis or undergoing dormancy. Before distant organ colonization, primary tumor

OCT 23, 2026 · JOURNAL ARTICLE

CASTOR1 functional inactivation drives KRAS -mutant NSCLC and therapy resistance by a noncanonical mechanism of tumor suppression

Science Advances

CASTOR1, a cytosolic arginine sensor and regulator of mTORC1 signaling, is identified here as a tumor suppressor in KRAS -driven non–small cell lung cancer (NSCLC). In a KRAS G12D

OCT 21, 2026 · JOURNAL ARTICLE

Furan fatty acids reprogram hepatic lipid metabolism via acyl-CoA conjugates in obesity

Science Advances

Dietary fish oil (FO) and omega-3 fatty acids are associated with cardiometabolic benefits, yet their molecular mediators remain incompletely defined. Furan fatty acids (FuFAs), a

OCT 21, 2026 · JOURNAL ARTICLE

BCG vaccination mitigates tau pathology and restores cognitive function in PS19 mice

Science Advances

Retrospective studies in patients with nonmuscle invasive bladder cancer have reported a significant reduction in Alzheimer’s disease incidence (12 to 78%) among Bacille Calmette-G

OCT 16, 2026 · JOURNAL ARTICLE

Programmable and selective silencing of oncogenic fusion transcripts by CRISPR-Cas13b via breakpoint sequence recognition

Science Advances

Oncogenic gene fusions are key drivers of cancer, yet most remain undruggable by current therapies. Here, we establish CRISPR- Psp Cas13b as a personalizable platform for systemati

OCT 16, 2026 · JOURNAL ARTICLE

PINK1-mediated mitophagy supports lung cancer initiation and limits the efficacy of KRAS -targeted therapy

Science Advances

Mitophagy, the selective degradation of mitochondria by lysosomes, is a major mitochondrial quality-control pathway, yet its role in lung cancer initiation and therapeutic response

OCT 16, 2026 · JOURNAL ARTICLE

Latent effector capacity governs reversible T cell exhaustion: A theoretical mathematical model of PD-1 blockade response

Science Advances

T cell exhaustion is often viewed as a terminal state marked by irreversible loss of function during chronic infection and cancer. However, the rapid recovery of antitumor activity

OCT 14, 2026 · JOURNAL ARTICLE

Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer

Science Advances

Immune checkpoint therapies have shown limited efficacy in metastatic castration-resistant prostate cancer (mCRPC). The AMADEUS prostate expansion cohort (NCT03651271) evaluated th